A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2004
11/17/2004	CN1547476A Use of ATAZANAVIR in HIV therapy
11/17/2004	CN1547475A Dermal therapy using phosphate derivatives of electron transfer agents
11/17/2004	CN1547474A Skin-permeable selective cyclooxygenase-2 inhibitor composition
11/17/2004	CN1547473A Methods for preventing antipsychotic-induced weight gain
11/17/2004	CN1547471A Combination comprising combretastatin and anticancer agents
11/17/2004	CN1176080C Indeno-, naphtho-, and benzocyclohepta-dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments
11/16/2004	US6818758 Estrogen receptor beta variants and methods of detection thereof
11/16/2004	US6818750 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferation or inflammatory disorders
11/16/2004	US6818745 For diagnosis/treatment of tumors; drug screening of antitumor agents; metastatic-tumor excreted phosphaturic-element (mepe/phosphatonin)
11/16/2004	US6818658 Treating obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
11/16/2004	US6818639 Combination of a 5-ht2c receptor agonist and a 5-ht6 receptor antagonist, or a salt, enantiomer or prodrug form
11/16/2004	US6818638 Melvinolin derivatives
11/16/2004	US6818630 Biologically active materials
11/16/2004	US6818624 Therapeutic agent for a cancer and method of screening the same, and health-care auxillary food
11/16/2004	US6818622 Selective MMP inhibitors having reduced side-effects
11/16/2004	US6818615 Antitumor, anticancer agents; synergistic mixture
11/16/2004	US6818445 Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
11/16/2004	US6818419 IRAK-4: compositions and methods of use
11/16/2004	US6818230 Antiproliferative effect can be achieved by subjecting conditioned medium obtained by culturing the structures of the invention in culture medium to filtration; anticancer agents
11/16/2004	US6818226 Dermal penetration enhancers and drug delivery systems involving same
11/16/2004	US6818224 Using fluid pharmaceutical which allows the controlled release of at least one active substance and which comprises active substance, phospholipid, solvent, fatty acid and can form gel instantaneously for therapy of periodontitis
11/16/2004	US6818214 Modulating cell proliferation or apoptosis comprising modulating psoriastatin activity
11/14/2004	CA2428564A1 Pharmaceutical composition for treatment of infection with drug resistant bacterium and disinfectant
11/11/2004	WO2004096963A1 Cosmetic and/or pharmaceutical preparations
11/11/2004	WO2004096275A1 Instrument for inducing cytokine and method of inducing cytokine
11/11/2004	WO2004096265A1 Nutrient liquid containing human growth hormone and the preparation method thereof
11/11/2004	WO2004096254A2 Transferrin conjugates for tumor treatment
11/11/2004	WO2004096250A1 Blood sugar regulating agent comprising a natural dry product derived from soya bean seeds alone or in a mixture and preparation thereof
11/11/2004	WO2004096243A1 Agent for preventing and ameliorating constipation
11/11/2004	WO2004096239A1 Method for administration of troxacitabine
11/11/2004	WO2004096228A1 Method of improved diuresis in individuals with impaired renal function
11/11/2004	WO2004096227A1 Pharmaceutical compositon comprising a cathepsin s inhibitor and an opioid
11/11/2004	WO2004096224A2 Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
11/11/2004	WO2004096222A1 Use of 1-(5-isoquinolinesulfonyl)homopiperazine, its active metabolites, isomers and salts for treating and preventing hypopigmentary disorders
11/11/2004	WO2004096216A2 Use of a topical medicament comprising riluzole
11/11/2004	WO2004096207A1 Body-temperature lowering depressant
11/11/2004	WO2004096206A2 Therapeutic combination of a cox-2 inhibitor and a tace inhibitor
11/11/2004	WO2004096200A1 Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse
11/11/2004	WO2004096194A2 Prevention of hiv-1 infection by inhibition of rho-mediated reorganization and/or content alteration of cell membrane raft domains
11/11/2004	WO2004096191A1 Pharmaceutical composition in the form of a hydrogel for transdermal administration of active substances
11/11/2004	WO2004096151A2 Methods and devices for the sustained release of multiple drugs
11/11/2004	WO2004096144A2 Compositions and methods for induction of opioid receptors
11/11/2004	WO2004096132A2 Combination of an aldosterone receptor antagonist and an anti-obesity agent
11/11/2004	WO2004096131A2 Inhibitors of akt activity
11/11/2004	WO2004096118A2 Composition for improving cognition and memory
11/11/2004	WO2004082579A3 Nemorubicin as radiosensitizer in combination with radiation therapy against tumors
11/11/2004	WO2004080482A3 Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure
11/11/2004	WO2004078133A3 Antineoplastic combinations comprising a rapamycin derivative and an aromatase inhibitor
11/11/2004	WO2004073614A3 Combination therapy for the treatment of immunoinflammatory disorders
11/11/2004	WO2004069274A3 Sensitizing cells for apoptosis by selectively blocking cytokines
11/11/2004	WO2004069209A3 Compositions and methods for increasing the sensitivity of apoptosis-resistant tumor cells to inducers of apoptosis
11/11/2004	WO2004066963A3 N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
11/11/2004	WO2004056305A3 Administration of capsaicinoids
11/11/2004	WO2004054511A3 Analgesic combination comprising nalbuphine
11/11/2004	WO2004039325A3 Treatment of pain with jnk inhibitors
11/11/2004	WO2004032872A3 Epo D + 5-FU/GEMCITABINE
11/11/2004	WO2004017917A3 Method for the prevention and/or treatment of atherosclerosis
11/11/2004	WO2003101394A3 Defensins: use as antiviral agents
11/11/2004	WO2003101380A3 Amyotrophic lateral sclerosis treatment with cyclooxygenase-2 inhibitors
11/11/2004	WO2003079973A3 Mitotic kinesin inhibitors
11/11/2004	WO2003077850A3 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
11/11/2004	WO2003063780A3 Therapeutic composition for treatment of cancer by arginine depletion
11/11/2004	WO2003060150A8 Nucleic acids encoding a g-protein coupled receptor involved in islet cell signaling
11/11/2004	WO2003046574A3 Complement c3 precursor biopolymer markers indicative of insulin resistance
11/11/2004	WO2003038052A3 Nucleic acid-associated proteins
11/11/2004	US20040225114 IGF-1 receptor interacting proteins
11/11/2004	US20040225002 Derivatives of isoindigo, indigo and indirubin and methods of treating cancer
11/11/2004	US20040224988 Administering 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole as dosage form to treat cancer
11/11/2004	US20040224986 Piperidinyl targeting compounds that selectively bind integrins
11/11/2004	US20040224981 Antibacterial methods and compositions
11/11/2004	US20040224975 Nicotinamide derivatives useful as PDE4 inhibitors
11/11/2004	US20040224970 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
11/11/2004	US20040224963 Neutralizes tobacco, nicotine addiction in mammals for cessation of smoking dependence
11/11/2004	US20040224962 Treatment of obesity with drugs and to promote weight loss using nicotinic receptors
11/11/2004	US20040224958 Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
11/11/2004	US20040224948 Novel substituted benzoxazines as integrin antagonists
11/11/2004	US20040224945 Novel substituted pyrazole derivatives
11/11/2004	US20040224940 Diagnosing a subject in need of treatment for a stroke; administering to the subject a cyclooxygenase-2 selective inhibitor or an isomer, a pharmaceutically acceptable salt, ester, or prodrug thereof and a sodium ion channel blocker
11/11/2004	US20040224932 crystal structure; antiinflammatory agents; antiallergens
11/11/2004	US20040224925 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs
11/11/2004	US20040224924 Programming a specific course and rate for a parent drug compound's metabolism that leads to an inactive or weakly active and non-toxic metabolite when the parent drug compound is administered, comprising modifying the parent drug compound by forming one or more of a predetermined chemical arrangement
11/11/2004	US20040224920 Methods of treatment of mitochondrial disorders
11/11/2004	US20040224919 Restoring cancer-suppressing functions to neoplastic cells through DNA hypomethylation
11/11/2004	US20040224917 Administering combination of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester fumarate (tenofovir disoproxil fumarate) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine)
11/11/2004	US20040224916 Administering combination comprising 9-[R-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine (GS-7340) or a physiologically functional derivative thereof, and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine)
11/11/2004	US20040224911 Transporters and ion channels
11/11/2004	US20040224910 Recombinant nematode nicotinic receptor and uses
11/11/2004	US20040224907 Compositions and methods for reversal of drug resistance
11/11/2004	US20040224885 Methods of treating hypertension and compositions for use therein
11/11/2004	US20040224884 drug screening; increasing bone mass without compromising bone strength or quality by administering an apototic or antiapoptotic agent that binds to the estrogen or androgen receptor without causing hormonal transcriptional activation; bone disorders
11/11/2004	US20040224881 drug screening for chloride channel blockers; osteoporosis, osteolytic cancer, osteopetrosis, Paget's disease; anticarcinogenic agents
11/11/2004	US20040224877 drug delivery method of deglycosylated Vitamin D binding protein (DBP-maf) for angiogenesis inhibition; anticarcinogenic, antitumor agents
11/11/2004	US20040224876 Combination therapy for the treatment of immunoinflammatory disorders
11/11/2004	US20040224424 Nucleotide sequences comprising allelic variant of cytochrome p450 for use in diagnosis and treatment of cell proliferative, nervous system and cardiovascular disorders; pharmacodynamic profiles and drug screening
11/11/2004	US20040224403 Reconstituting hematopoietic cell function using human embryonic stem cells
11/11/2004	US20040224378 Methods for using ADAMTS-12, an integrin and metalloprotease with thrombspondin motifs
11/11/2004	US20040224363 Immunoglobulin for use in diagnosis and prognosis of metastatic breast cancer and degenerative neural conditions; drug screening; immunotherapy and diagnostics; anticarcinogenic agents
11/11/2004	US20040224360 Methods for diagnosing renal disorders
11/11/2004	US20040224356 Novel human enzymes of the metalloprotease family
11/11/2004	US20040224355 Using guanylate cyclase gene expression for imaging and treating primary and/or metastatic stomach or esophageal cancer; tissue targeted therapy; genetic vaccines; immunotherapy

1 ... 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 ... 1151